# Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

> **NCT04191187** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 34 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Biphenotypic Acute Leukemia
- Undifferentiated Leukemia
- Prolymphocytic Leukemia
- Myelodysplastic Syndromes
- Chronic Myelogenous Leukemia
- Myeloproliferative Neoplasm
- Relapsed Large Cell Lymphoma
- Mantle Cell Lymphoma
- Hodgkin Lymphoma
- Burkitt Lymphoma
- Relapsed T-Cell Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Relapsed Small Lymphocytic Lymphoma
- Relapsed Marginal B-cell Lymphoma
- Relapsed Follicular Lymphoma
- Lymphoplasmacytic Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **RADIATION:** Total Body Irradiation

## Key facts

- **NCT ID:** NCT04191187
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-06
- **Primary completion:** 2024-02-11
- **Final completion:** 2024-02-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04191187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04191187, "Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04191187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*